688626 翔宇医疗
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入337,8590.93%744,810488,529523,496495,514
减:营业总成本285,34318.39%529,660414,020358,786321,164
    其中:营业成本107,376-0.96%233,715164,762166,316159,789
               财务费用(11,272)-17.23%(29,813)(26,644)(23,977)(12,592)
               资产减值损失(3,057)-3.64%(12,117)(5,952)(2,777)(2,157)
公允价值变动收益------------
投资收益1,338-74.28%9,29313,65212,125(311)
    其中:对联营企业和合营企业的投资收益159-148.38%(540)(2,062)(1,840)(585)
营业利润61,330-46.16%244,629135,463224,059223,350
利润总额61,118-46.31%244,031132,992222,721222,786
减:所得税费用4,527-15.42%15,7179,69723,18226,776
净利润56,591-47.83%228,314123,295199,539196,010
减:非控股权益(45)-105.20%1,171(2,175)(2,359)(253)
股东净利润56,636-47.37%227,143125,470201,897196,263

市场价值指针
每股收益 (元) *0.360-47.06%1.4400.7901.3501.640
每股派息 (元) *----0.5300.2400.3800.370
每股净资产 (元) *12.5841.18%13.06812.04712.0946.196
审计意见 #--标准无保留意见标准无保留意见标准无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容